B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2013, Trends, Share, Size Research Report

Global Markets Directs, B-Cell Non-Hodgkin Lymphoma Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma. B-Cell Non-Hodgkin Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

A snapshot of the global therapeutic scenario for B-Cell Non-Hodgkin Lymphoma.
A review of the B-Cell Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the B-Cell Non-Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 10
Global Markets Direct Report Coverage 10
B-Cell Non-Hodgkin Lymphoma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for B-Cell Non-Hodgkin Lymphoma 12
B-Cell Non-Hodgkin Lymphoma Therapeutics under Development by Companies 14
B-Cell Non-Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
B-Cell Non-Hodgkin Lymphoma Therapeutics Products under Development by Companies 25
B-Cell Non-Hodgkin Lymphoma Therapeutics Products under Investigation by Universities/Institutes 31
Companies Involved in B-Cell Non-Hodgkin Lymphoma Therapeutics Development 32
Bristol-Myers Squibb Company 32
Johnson & Johnson 33
Boehringer Ingelheim GmbH 34
F. Hoffmann-La Roche Ltd. 35
Kyowa Hakko Kirin Co., Ltd. 36
Biogen Idec Inc. 37
Amgen Inc. 38
Sanofi-Aventis 39
AstraZeneca PLC 40
Eli Lilly and Company 41
Seattle Genetics, Inc. 42
Genentech, Inc. 43
MedImmune LLC 44
Gilead Sciences, Inc. 45
Merck & Co., Inc. 46
Infinity Pharmaceuticals, Inc. 47
Reliance Life Sciences Pvt. Ltd. 48
Piramal Healthcare Limited 49
Celltrion, Inc. 50
Millennium Pharmaceuticals, Inc. 51
Novartis AG 52
Astellas Pharma Inc. 53
Biocon Limited 54
Ono Pharmaceutical Co., Ltd. 55
Pfizer Inc. 56
SuperGen, Inc. 57
Teva Pharmaceutical Industries Limited 58
Cell Therapeutics, Inc. 59
Genmab A/S 60
Sandoz Inc. 61
Celgene Corporation 62
Onyx Pharmaceuticals, Inc. 63
Bayer AG 64
Merck KGaA 65
AEterna Zentaris Inc. 66
IMMUNOMEDICS, INC 67
MethylGene Inc 68
Accentia Biopharmaceuticals, Inc. 69
Portola Pharmaceuticals, Inc. 70
Pharmacyclics, Inc. 71
Senesco Technologies, Inc. 72
Cancer Research Technology Limited 73
Spectrum Pharmaceuticals, Inc. 74
Memgen, LLC. 75
Abiogen Pharma S.p.A. 76
Provenance Biopharmaceuticals Corp. 77
Constellation Pharmaceuticals, Inc. 78
Stemline Therapeutics, Inc. 79
Onconova Therapeutics, Inc 80
Immune System Therapeutics Ltd. 81
AmpliMed Corporation 82
CureTech Ltd. 83
LFB Biotechnologies, S.A.S.U. 84
Areta International s.r.l. 85
Molecular Templates Inc. 86
Synthon BV 87
Cell>Point 88
Coridon Pty Ltd 89
Advancell 90
B-Cell Non-Hodgkin Lymphoma Therapeutics Assessment 91
Assessment by Monotherapy Products 91
Assessment by Route of Administration 92
Assessment by Molecule Type 94
Drug Profiles 97
perifosine - Drug Profile 97
veltuzumab - Drug Profile 100
bendamustine hydrochloride - Drug Profile 103
CEP-9722 - Drug Profile 105
obinutuzumab - Drug Profile 106
obinutuzumab - Drug Profile 108
SAR-3419 - Drug Profile 110
pacritinib - Drug Profile 112
blinatumomab - Drug Profile 114
brentuximab vedotin - Drug Profile 117
acadesine - Drug Profile 121
SGN-CD19A - Drug Profile 123
mocetinostat - Drug Profile 124
ibrutinib - Drug Profile 127
ibrutinib - Drug Profile 130
ibrutinib - Drug Profile 133
abexinostat hydrochloride - Drug Profile 136
SAR-245409 - Drug Profile 138
SAR-245409 - Drug Profile 140
agatolimod sodium - Drug Profile 142
dasiprotimut T - Drug Profile 144
dasiprotimut T - Drug Profile 146
BLX-301 - Drug Profile 148
AT-7519 - Drug Profile 149
bortezomib - Drug Profile 151
bortezomib - Drug Profile 155
bortezomib - Drug Profile 159
DI-Leu16-IL2 - Drug Profile 163
MDX-1097 - Drug Profile 164
carfilzomib - Drug Profile 165
Afinitor - Drug Profile 168
idelalisib - Drug Profile 171
idelalisib - Drug Profile 173
ISF-35 - Drug Profile 175
imexon - Drug Profile 177
SL-101 - Drug Profile 179
ON-013105 - Drug Profile 180
ibritumomab tiuxetan - Drug Profile 181
pralatrexate - Drug Profile 183
MLN-0128 - Drug Profile 186
siltuximab - Drug Profile 188
BMS-936564 - Drug Profile 192
pidilizumab - Drug Profile 193
P-1446 - Drug Profile 195
Autologous Recombinant Idiotypic Vaccine - Drug Profile 197
MEDI-551 - Drug Profile 198
KW-2478 - Drug Profile 200
epratuzumab - Drug Profile 201
X-339 - Drug Profile 206
Combotox - Drug Profile 207
buparlisib - Drug Profile 208
palbociclib - Drug Profile 211
inotuzumab ozogamicin - Drug Profile 214
lenalidomide - Drug Profile 216
lenalidomide - Drug Profile 219
urelumab - Drug Profile 222
DI-Leu16-IL2 Immunocytokine - Drug Profile 223
simvastatin - Drug Profile 224
ofatumumab - Drug Profile 225
ofatumumab - Drug Profile 229
fostamatinib disodium - Drug Profile 233
LY-2835219 - Drug Profile 236
Autologous Or Syngeneic PBTL And EBV Specific CTL - Drug Profile 237
bevacizumab - Drug Profile 238
rituximab - Drug Profile 242
ocaratuzumab - Drug Profile 245
scFV-Chemokine DNA Vaccine - Drug Profile 247
Therapeutic Tumor Infiltrating Lymphocytes - Drug Profile 248
CC-292 - Drug Profile 249
IPI-145 - Drug Profile 251
EMD-521873 - Drug Profile 253
rituximab biosimilar - Drug Profile 254
rituximab biosimilar - Drug Profile 256
RG-7593 - Drug Profile 258
Dendritic Cell Vaccine - Drug Profile 260
rituximab biosimilar - Drug Profile 261
rituximab biosimilar - Drug Profile 262
RG-7596 - Drug Profile 263
BI-836826 - Drug Profile 265
ABT-199 - Drug Profile 266
rituximab biosimilar - Drug Profile 269
Platinum-Ethylenedicysteine-Glucosamine - Drug Profile 270
187 Rhenium-Ethylenedicysteine N- AcetylGlucosamine - Drug Profile 271
GS-9973 - Drug Profile 272
ONO-4059 - Drug Profile 273
SEL-120 Program - Drug Profile 274
Anti-CD19-CAR-Transduced T Cells - Drug Profile 275
KPT-330 - Drug Profile 276
rituximab biosimilar - Drug Profile 278
tretinoin - Drug Profile 279
131I-Rituximab - Drug Profile 280
BCL-6 Inhibitor - Drug Profile 281
BET Inhibitor Program - Drug Profile 282
Recombinant Idiotypic VK3-20 Vaccine - Drug Profile 283
ND-2110 - Drug Profile 284
ND-2158 - Drug Profile 286
PRT-060318 - Drug Profile 288
Epstein Barr Virus Vaccine - Drug Profile 289
Andrographolide - Drug Profile 290
pecazine - Drug Profile 291
thioridazine - Drug Profile 292
interferon alfa-2b biosimilar - Drug Profile 293
BM-ca - Drug Profile 294
DNA Fusion Vaccines - Drug Profile 295
MT-3724 - Drug Profile 297
HCQ/CLB-Loaded Anti-CD20 Antibody - Drug Profile 299
B-Cell Non-Hodgkin Lymphoma Therapeutics Drug Profile Updates 300
B-Cell Non-Hodgkin Lymphoma Therapeutics Discontinued Products 432
B-Cell Non-Hodgkin Lymphoma Therapeutics - Dormant Products 434
B-Cell Non-Hodgkin Lymphoma Product Development Milestones 439
Featured News & Press Releases 439

Appendix 452
Methodology 452
Coverage 452
Secondary Research 452
Primary Research 452
Expert Panel Validation 452
Contact Us 453
Disclaimer 453

List of Table

Number of Products Under Development for B-Cell Non-Hodgkin Lymphoma, H2 2013 19
Products under Development for B-Cell Non-Hodgkin Lymphoma Comparative Analysis, H2 2013 20
Number of Products under Development by Companies, H2 2013 22
Number of Products under Development by Companies, H2 2013 (Contd..1) 23
Number of Products under Development by Companies, H2 2013 (Contd..2) 24
Number of Products under Development by Companies, H2 2013 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2013 27
Comparative Analysis by Late Stage Development, H2 2013 28
Comparative Analysis by Mid Clinical Stage Development, H2 2013 29
Comparative Analysis by Early Clinical Stage Development, H2 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 31
Products under Development by Companies, H2 2013 32
Products under Development by Companies, H2 2013 (Contd..1) 33
Products under Development by Companies, H2 2013 (Contd..2) 34
Products under Development by Companies, H2 2013 (Contd..3) 35
Products under Development by Companies, H2 2013 (Contd..4) 36
Products under Development by Companies, H2 2013 (Contd..5) 37
Products under Investigation by Universities/Institutes, H2 2013 38
Bristol-Myers Squibb Company, H2 2013 39
Johnson & Johnson, H2 2013 40
Boehringer Ingelheim GmbH, H2 2013 41
F. Hoffmann-La Roche Ltd., H2 2013 42
Kyowa Hakko Kirin Co., Ltd., H2 2013 43
Biogen Idec Inc., H2 2013 44
Amgen Inc., H2 2013 45
Sanofi-Aventis, H2 2013 46
AstraZeneca PLC, H2 2013 47
Eli Lilly and Company, H2 2013 48
Seattle Genetics, Inc., H2 2013 49
Genentech, Inc., H2 2013 50
MedImmune LLC, H2 2013 51
Gilead Sciences, Inc., H2 2013 52
Merck & Co., Inc., H2 2013 53
Infinity Pharmaceuticals, Inc., H2 2013 54
Reliance Life Sciences Pvt. Ltd., H2 2013 55
Piramal Healthcare Limited, H2 2013 56
Celltrion, Inc., H2 2013 57
Millennium Pharmaceuticals, Inc., H2 2013 58
Novartis AG, H2 2013 59
Astellas Pharma Inc., H2 2013 60
Ono Pharmaceutical Co., Ltd., H2 2013 62
Pfizer Inc., H2 2013 63
SuperGen, Inc., H2 2013 64
Teva Pharmaceutical Industries Limited, H2 2013 65
Cell Therapeutics, Inc., H2 2013 66
Genmab A/S, H2 2013 67
Sandoz Inc., H2 2013 68
Celgene Corporation, H2 2013 69
Onyx Pharmaceuticals, Inc., H2 2013 70
Bayer AG, H2 2013 71
Merck KGaA, H2 2013 72
AEterna Zentaris Inc., H2 2013 73
IMMUNOMEDICS, INC, H2 2013 74
MethylGene Inc, H2 2013 75
Accentia Biopharmaceuticals, Inc., H2 2013 76
Portola Pharmaceuticals, Inc., H2 2013 77
Pharmacyclics, Inc., H2 2013 78
Cancer Research Technology Limited, H2 2013 80
Spectrum Pharmaceuticals, Inc., H2 2013 81
Memgen, LLC., H2 2013 82
Abiogen Pharma S.p.A., H2 2013 83
Provenance Biopharmaceuticals Corp., H2 2013 84
Constellation Pharmaceuticals, Inc., H2 2013 85
Stemline Therapeutics, Inc., H2 2013 86
Onconova Therapeutics, Inc, H2 2013 87
Immune System Therapeutics Ltd., H2 2013 88
AmpliMed Corporation, H2 2013 89
CureTech Ltd., H2 2013 90
LFB Biotechnologies, S.A.S.U., H2 2013 91
Areta International s.r.l., H2 2013 92
Molecular Templates Inc., H2 2013 93
Synthon BV, H2 2013 94
Cell>Point, H2 2013 95
Coridon Pty Ltd, H2 2013 96
Advancell, H2 2013 97
Assessment by Monotherapy Products, H2 2013 98
Assessment by Stage and Route of Administration, H2 2013 100
Assessment by Stage and Molecule Type, H2 2013 103
B-Cell Non-Hodgkin Lymphoma Therapeutics Drug Profile Updates 307
B-Cell Non-Hodgkin Lymphoma Therapeutics Discontinued Products 439
B-Cell Non-Hodgkin Lymphoma Therapeutics Discontinued Products (Contd..1) 440
B-Cell Non-Hodgkin Lymphoma Therapeutics Dormant Products 441
B-Cell Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..1) 442
B-Cell Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..2) 443
B-Cell Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..3) 444
B-Cell Non-Hodgkin Lymphoma Therapeutics Dormant Products (Contd..4) 445

List of Chart

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H2 2013 19
Products under Development for B-Cell Non-Hodgkin Lymphoma Comparative Analysis, H2 2013 20
Products under Development by Companies, H2 2013 21
Products under Investigation by Universities/Institutes, H2 2013 26
Late Stage Products, H2 2013 28
Mid Clinical Stage Products, H2 2013 29
Early Clinical Stage Products, H2 2013 30
Discovery and Pre-Clinical Stage Products, H2 2013 31
Assessment by Monotherapy Products, H2 2013 98
Assessment by Route of Administration, H2 2013 99
Assessment by Stage and Route of Administration, H2 2013 100
Assessment by Molecule Type, H2 2013 101
Assessment by Stage and Molecule Type, H2 2013 102

Ask for discount before buying this report

Please fill the enquiry form below.

Full Name *
Your Email *
Job Title
Company *
Phone No. * (Pls. Affix Country Code)
Country :

Your Requirement
Security Code *
94244

* denotes fields which must be completed

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2013

List of Table

List of Chart

Buy This Report

Have Query?

Research Assistance